{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:31Z","timestamp":1787063131272,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01581-9","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:48:34Z","timestamp":1783662514000},"page":"1031-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Altered Busulphan Exposure Associated with Concomitant Omeprazole during Hematopoietic Stem Cell Transplantation Conditioning: A Two-Case Report"],"prefix":"10.1007","volume":"46","author":[{"given":"Ibrahim","family":"El-Serafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustapha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"11","key":"1581_CR1","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526\u201336.","journal-title":"Lancet Haematol."},{"issue":"8","key":"1581_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/17425250903107764","volume":"5","author":"JS McCune","year":"2009","unstructured":"McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5(8):957\u201369.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1581_CR3","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","volume":"84","author":"M Hassan","year":"1994","unstructured":"Hassan M, Ljungman P, Bolme P, Ringd\u00e9n O, Syr\u016fckov\u00e1 Z, B\u00e9k\u00e0ssy A, et al. Busulfan bioavailability. Blood. 1994;84(7):2144\u201350.","journal-title":"Blood"},{"issue":"1","key":"1581_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55\u201361.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1581_CR5","unstructured":"Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res. 1994;14(6A):2363-70."},{"issue":"11","key":"1581_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187294","volume":"12","author":"I El-Serafi","year":"2017","unstructured":"El-Serafi I, Terelius Y, Abedi-Valugerdi M, Naughton S, Saghafian M, Moshfegh A, et al. Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS ONE. 2017;12(11):e0187294.","journal-title":"PLoS ONE"},{"issue":"4","key":"1581_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00007691-200008000-00003","volume":"22","author":"M Hassan","year":"2000","unstructured":"Hassan M, Svensson JO, Nilsson C, Hentschke P, Al-Shurbaji A, Aschan J, et al. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Ther Drug Monit. 2000;22(4):383\u20135.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1581_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.bmt.1703896","volume":"31","author":"C Nilsson","year":"2003","unstructured":"Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(6):429\u201335.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1581_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/tpj.2013.38","volume":"14","author":"CR Uppugunduri","year":"2014","unstructured":"Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, et al. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J. 2014;14(3):263\u201371.","journal-title":"Pharmacogenomics J"},{"key":"1581_CR10","first-page":"107","volume":"11","author":"NP Denisenko","year":"2018","unstructured":"Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018;11:107\u201312.","journal-title":"Pharmgenomics Pers Med"},{"key":"1581_CR11","unstructured":"Shah N, Gossman W. Omeprazole. StatPearls. Treasure Island (FL); 2020."},{"issue":"1","key":"1581_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40261-013-0148-z","volume":"34","author":"F Sjoo","year":"2014","unstructured":"Sjoo F, El-Serafi I, Enestig J, Mattsson J, Liwing J, Hassan M. Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate. Clin Drug Investig. 2014;34(1):43\u201352.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1581_CR13","first-page":"843","volume":"18","author":"M Hassan","year":"1996","unstructured":"Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, van den Berg H, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996;18(5):843\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1581_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3346\/jkms.2017.32.5.729","volume":"32","author":"S Park","year":"2017","unstructured":"Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM, et al. Effects of CYP2C19 genetic polymorphisms on PK\/PD responses of omeprazole in Korean healthy volunteers. J Korean Med Sci. 2017;32(5):729\u201336.","journal-title":"J Korean Med Sci"},{"issue":"11","key":"1581_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141979","volume":"10","author":"I El-Serafi","year":"2015","unstructured":"El-Serafi I, Afsharian P, Moshfegh A, Hassan M, Terelius Y. Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation. PLoS ONE. 2015;10(11):e0141979.","journal-title":"PLoS ONE"},{"issue":"11","key":"1581_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/FPC.0b013e328358d92b","volume":"22","author":"L Hu","year":"2012","unstructured":"Hu L, Zhuo W, He YJ, Zhou HH, Fan L. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet Genomics. 2012;22(11):812\u20139.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1581_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","volume":"41","author":"V Gandhi","year":"2002","unstructured":"Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93\u2013103.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01581-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01581-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01581-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:48Z","timestamp":1787059968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01581-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01581-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Karolinska Institutet (Dnr. 65\/03 and 616\/03) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from both patients to participate in this study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from both patients to publish this study.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed in the current study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.E.-S. designed the experiments, participated in the investigations and data analysis, and wrote the original draft and the final manuscript. R.H. participated in the investigations and data analysis, and wrote the final manuscript. Y.Z. participated in the investigations and data analysis, and wrote the final manuscript. J.M. designed the experiments, participated in the data analysis, and wrote the final manuscript. M.H. designed the experiments, participated in the data analysis, supervised some of the co-authors, and wrote the original draft and the final version. All authors read and approved the final version and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}